NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models

The immunosuppressive character of head and neck cancers may explain the relatively low response rates to antibody therapy targeting a tumor antigen, such as cetuximab, and anti-PD-1 checkpoint inhibition. Immunostimulatory agents that overcome tumor-derived inhibitory signals could augment therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruijs, Mandy, Ganzevles, Sonja H., Stigter-van Walsum, Marijke, van der Mast, Richard, van Ostaijen-ten Dam, Monique M., Tuk, Cornelis W., Schilham, Marco W., Leemans, C. René, Brakenhoff, Ruud H., van Egmond, Marjolein, van de Ven, Rieneke, Bakema, Jantine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541276/
https://www.ncbi.nlm.nih.gov/pubmed/34681717
http://dx.doi.org/10.3390/ijms222011057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541276/
https://www.ncbi.nlm.nih.gov/pubmed/34681717
http://dx.doi.org/10.3390/ijms222011057

Ejemplares similares